Coya Therapeutics, Inc. Secures $10 Million in Funding to Advance Groundbreaking Treg-focused Therapies

Coya Therapeutics, Inc. (Nasdaq: COYA), the Houston-based clinical-stage biotechnology company, has successfully raised $10 million in a recent funding round aimed at catalyzing its innovative research and development efforts. Known for its groundbreaking work in targeting systemic inflammation and neuroinflammation through the modulation of regulatory T cells (Tregs), Coya Therapeutics is at the forefront of addressing critical medical needs in the realms of neurodegenerative, metabolic, and autoimmune diseases. The newly acquired funding will primarily support the advancement of Coya’s 300 Series product candidates—COYA 301 and COYA 302—both of which are designed to enhance Treg function and augment Treg populations. COYA 301 is a cytokine biologic intended for subcutaneous administration, while COYA 302 is a dual-action biologic that can be administered subcutaneously or intravenously to target Treg functionality and diminish the activity of T effector cells and activated macrophages. With this financial boost, Coya aims to accelerate the clinical development of these promising treatments, potentially offering new hope to patients suffering from debilitating conditions characterized by chronic inflammation and immune system dysfunction. Coya Therapeutics remains steadfast in its mission to pioneer innovative therapeutics that fulfill unmet medical needs, emphasizing its commitment to improving the quality of life for patients facing serious health challenges. For further insights into Coya’s trailblazing therapies and vision, please visit www.coyatherapeutics.com.